Demonstrating high efficacy and safety^3-9, Kleresca® Rosacea Treatment is based on photobiomodulation (PBM) – a non-invasive biophotonic technology that uses fluorescent light energy to stimulate the skin’s own repair mechanisms^1,3. The treatment is designed to treat rosacea symptoms comfortably with little to no downtime^3-9

The treatment causes no photo sensitivity and is suitable for patients including those with enhanced skin sensitivity throughout the year incl. summertime².

Prevalence of rosacea

Rosacea is an inflammatory skin disorder that primarily affects the cheeks, nose, chin and central forehead^11,12. Its psychological and emotional impact on patients can be severe ^13,14. It is estimated that approximately 415 million people worldwide have rosacea¹⁵.  The condition can affect all skin types but is most commonly seen in people with fair skin^16,17.

Benefits of Kleresca® Rosacea Treatment

While being gentle with high efficacy and safety, this in-clinic treatment offers patients the following benefits^3-5,8-10:

• Reduces inflammation, reducing the presence of papules and pustules
• Reduces erythema and blushing by improving microvascularisation
• Reduces the overall stress level of the skin, thereby reducing the feeling of burning and stinging
• Induces a healing response, improving the overall skin quality

Kleresca® Rosacea Treatment combines multi-LED light with a special photoconverter gel to produce fluorescent light energy which improve the overall quality of the skin^3-9.

Treatment procedure and availability

The Kleresca® Rosacea Treatment is offered exclusively in professional clinics in Italy. Upon medical assessment, a trained professional will cleanse the patient’s skin and apply the gel which is illuminated under a multi-wavelength LED light for nine minutes each session². There is limited to no downtime^3-9 after the treatment and make up can be applied afterwards. A treatment for rosacea will include an initial regime of app. 4-6 consecutive sessions depending on the severity of the condition. Number of treatments varies from patient to patient and is subject to the evaluation of the treating clinician².

Efficacy and safety

Patients who are treated with Kleresca® Rosacea Treatment should see long-lasting, noticeable improvements to the skin as the repair mechanisms progress over the course of treatment as well as after the treatment has ended^3,4.Side effects seen in some patients may include redness, hyperpigmentation (bronzing of an area of the skin) and hair bleaching. All registered side effects have been transient with no need of clinic intervention^3-9.

 “Living with rosacea can have a big impact on a person’s confidence, increasing the risk of social anxiety and depression. Rosacea is seen to increase in severity over time, so it is important to seek professional help as early as possible” says Dr Giuseppe Scarcella, Dermatologist based in Verona.

Four subtypes of rosacea^11,12 

Main symptoms of rosacea are redness, skin becoming easily flushed, sensitive skin, pimples and fine red vascular lines (telangiectasias)^11,12. Depending on the subtype of rosacea, it can be also expressed as rhinophyma (enlarged nose) or eye problems (swollen, red eyelids and conjunctivitis)^11,12. Kleresca® Rosacea Treatment is suitable for subtype 1-3 (excluding subtype expressed in eyes)⁹. Kleresca® also offers treatments for acne and skin rejuvenation based on the PBM technology.

1. Nielsen, M.E., et al (2017). Introducing: photobiomodulation by low energy chromophore-induced fluorescent light. Mechanisms of Photobiomodulation Therapy IV, SPIE Photonics West BIOS, San Francisco, 2017; 28 January – 2 February
2. Kleresca® Rosacea Treatment Instruction for Use
3. Jalili, A. 2018. Chromophore gel-assisted phototherapy. A novel and promising photobiomodulation therapy for facial inflammatory skin diseases and skin aging. J Ästhet Chir. 2018. Early online 20 February
4. Nikolis, A.  et al. An extension of a multicenter, randomized, split-face clinical trial evaluating the efficacy and safety of chromophore gel-assisted blue light phototherapy for the treatment of acne. Int. J. Dermatol. 2017; Accetped
5. Antoniou, C.et al . A multicenter, randomized, split-face clinical trial evaluating the efficacy and safety of chromophore gel-assisted blue light phototherapy for the treatment of acne. 2016; Int J Dermatol, 2016, 55; 1321 – 1328
6. Nikolis, A., et al . A randomized, placebo-controlled, single-blinded, split-faced clinical trial evaluating the efficacy and safety of KLOX-001 gel formulation with KLOX light-emitting diode light on facial rejuvenation. Clinical, Cosmetic and Investigational Dermatology, 2016; 9, 115–25.
7. Scarcella et al. 2018,. Treatment of solar lentigines using a combination of PICO-Laser and Biophotonic treatment. Int J Dermatol (In press)
8. Braun, S.A.& Gerber, P. A photoconverter-gel assited blue light therapy for the treatment of rosacea. Int. K Dermatol. 2017 [Epub ahead of print]
9. Sannino, M. et al. A novel platform for treating rosacea subtypes 1, 2 and 3 using fluorescent light. Int J Dermatol 2018. In press
10. Nielsen, Schoedt & Bak-Christensen. Clinical Evaluation – Kleresca® Biophotonic Treatments. 2017. Kleresca® Data on File
11. Wilkin, J., et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004 Jun;50(6):907-12.
12. Wilkin, J., et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002 Apr;46(4):584-7.
13. Zeichner, A., et al. Quality of Life in individuals with erythematotelangiectatic and papulopustular rosacea: findings from a web-based survey. J Clin Aesthet Dermatol. 2018; 11(2):47 – 52
14. Say, E.M., et al. Treatment Outcomes of Long-Pulsed Nd: YAG Laser for Two Different Subtypes of Rosacea. J Clin Aesthet Dermatol. 2015 Sep;8(9):16-20.
15. L et al. Incidence and Prevalence of Rosacea: a systematic review and meta-analysis. Br. J. Dermatol 2018 [Epub ahead of print]
16. Stanisław Jarmuda, Niamh O’Reilly, Ryszard Z˙aba, Oliwia Jakubowicz, Andrzej Szkaradkiewicz and Kevin Kavanagh. (2012). Potential role of Demodex mites and bacteria in the induction of rosacea. Journal of Medical Microbiology, 61, 1504–1510.
17. Thomas Jansen and Gerd Plewig. (1997). Rosacea: classification and treatment. Journal of the Royal Society of Medicine, 144-150.